Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases

Liver International

Volumn 27, Issue 1, 2007, Pages 95-100

  Tamori, Akihiro ^a   Shinzaki, Mayumi ^a   Kosaka, Saori ^a   Hayashi, Takehiro ^a   Iwai, Shuji ^a   Enomoto, Masaru ^a   Habu, Daiki ^a   Sakaguchi, Hiroki ^a   Kawada, Norifumi ^a   Hino, Masayuki ^a   Shiomi, Susumu ^a   Nishiguchi, Shuhei ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Autoimmune hepatitis; Azathioprine; Polymorphism; Primary biliary cirrhosis; Thiopurine S methyltransferase

Indexed keywords

AZATHIOPRINE; PREDNISOLONE; THIOPURINE METHYLTRANSFERASE;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GRANULOCYTOPENIA; HEPATITIS C; HOMOZYGOSITY; HUMAN; JAPANESE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIMARY BILIARY CIRRHOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; THROMBOCYTOPENIA; VIRUS HEPATITIS; VOLUNTEER;

ADULT; AGED; AGRANULOCYTOSIS; ASIAN CONTINENTAL ANCESTRY GROUP; AZATHIOPRINE; BONE MARROW; FEMALE; GASTROINTESTINAL DISEASES; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLTRANSFERASES; MIDDLE AGED; POLYMORPHISM, GENETIC; THROMBOCYTOPENIA;

EID: 33846426869     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01392.x     Document Type: Article

References (33)

1. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-39.
2. Deininger M, Szumlanski CL, Otterness DM, Van Loon J, Ferber W, Weinshilboum RM. Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol 1994; 48: 2135-8.
3. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 60-73.
4. Spire-Vayron de la Moureyre C, Debuysere H, Sabbagh N, et al. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998; 12: 177-85.
5. Okada Y, Nakamura K, Wada M, et al. Genotyping of thiopurine methyltransferase using pyrosequencing. Biol Pharm Bull 2005; 28: 677-81.
6. Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: Molecular mechanisms and clinical importance. Pharmacology 2000; 61: 136-46.
7. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9: 37-42.
8. Kumagai K, Hiyama K, Ishioka S, et al. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 2001; 11: 275-8.
9. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006; 43: S132-44.
10. Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: Safety and efficacy of prolonged medical therapy. Liver Int 2005; 25: 734-9.
11. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002; 35: 7-13.
12. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-63.
13. Bajaj JS, Saeian K, Varma RR, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: A tertiary referral center experience. Am J Gastroenterol 2005; 100: 1121-5.
14. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
15. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 1149-57.
16. Ben Ari Z, Mehta A, Lennard L, Burroughs AK. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995; 23: 351-4.
17. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002; 37: 441-7.
18. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
19. Ward V, Hennig BJ, Hirai K, et al. Geographical distribution and disease associations of the CD45 exon 6 138G variant. Immunogenetics 2006; 58: 235-9.
20. Corominas H, Domenech M, Gonzalez D, et al. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. Am J Gastroenterol 2000; 95: 2313-7.
21. Okada Y, Nakamura K, Kodama T, et al. Thiopurine methyltransferase genotype and phenotype status in Japanese patients with systemic lupus erythematosus. Biol Pharm Bull 2005; 28: 2117-9.
22. Kubota T, Chiba K. Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and 3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. Br J Clin Pharmacol 2001; 51: 475-7.
23. Yoshizawa K, Ota M, Katsuyama Y, et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol 2005; 42: 578-84.
24. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006; 45: 584-91.
25. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: Impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-36.
26. Clunie GP, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford) 2004; 43: 13-8.
27. Kubota T, Nishida A, Takeuchi K, et al. Frequency distribution of thiopurine S-methyltransferase activity in red blood cells of a healthy Japanese population. Ther Drug Monit 2004; 26: 319-21.
28. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford) 1999; 38: 640-4.
29. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine therapy in inflammatory bowel disease. Gut 2006; 16 [Epub ahead of print].
30. Otterness DM, Szumlanski CL, Wood TC, Weinshilboum RM. Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest 1998; 101: 1036-44.
31. Falta MT, Atkinson MA, Allegretta M, Vacek PM, Albertini RJ. Azathioprine associated T-cell mutations in insulin-dependent diabetes mellitus. Scand J Immunol 2000; 51: 626-33.
32. Albertini RJ. HPRT mutations in humans: Biomarkers for mechanistic studies. Mutat Res 2001; 489: 1-16.
33. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99: 1744-8.